H Ahman
Overview
Explore the profile of H Ahman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kayhty H, Ahman H
Clin Infect Dis
. 2001 Dec;
33 Suppl 4:S292-8.
PMID: 11709762
Pneumococcal conjugate vaccines (PncCs) will be introduced into childhood vaccination programs now that the first PncC has been licensed for use. The next generation of PncCs and possible combination vaccines...
2.
Nurkka A, Ahman H, Yaich M, Eskola J, Kayhty H
Vaccine
. 2001 Sep;
20(1-2):194-201.
PMID: 11567764
We studied the immunogenicity of two octavalent pneumococcal (Pnc) conjugate vaccines; Pnc polysaccharides (PS) of serotypes 3, 4, 6B, 9V, 14, 18C, 19F, and 23F were conjugated to diphtheria or...
3.
Wuorimaa T, Dagan R, Eskola J, JANCO J, Ahman H, Leroy O, et al.
Pediatr Infect Dis J
. 2001 Apr;
20(3):272-7.
PMID: 11303829
Background: A need to increase the serotype coverage of pneumococcal conjugate vaccines exists. The use of a single carrier protein may cause overload of the carrier and decrease the immune...
4.
Nurkka A, Ahman H, Korkeila M, Jantti V, Kayhty H, Eskola J
Pediatr Infect Dis J
. 2001 Feb;
20(1):25-33.
PMID: 11176563
Aim: To study the ability of seven-valent experimental pneumococcal polysaccharide CRM197 protein conjugate vaccine (PncCRM) to induce antibodies in serum and saliva of infants. Methods: Sixty Finnish infants received Pnc-CRM...
5.
Korkeila M, Lehtonen H, Ahman H, Leroy O, Eskola J, Kayhty H
Vaccine
. 2000 Jan;
18(13):1218-26.
PMID: 10649623
Saliva samples of infants and children immunised with pneumococcal vaccines were analysed for anti-polysaccharide (PS) antibodies against the Streptococcus pneumoniae (Pnc) vaccine serotypes 6B, 14, 19F, and 23F. The children...
6.
Ahman H, Kayhty H, Vuorela A, Leroy O, Eskola J
Vaccine
. 1999 Jul;
17(20-21):2726-32.
PMID: 10418924
Three injections of tetravalent pneumococcal polysaccharide-tetanus toxoid conjugate vaccine (PncT) were given to infants at 2, 4 and 6 months of age simultaneously with diphtheria-tetanus-pertussis and Haemophilus influenzae type b-tetanus...
7.
Anttila M, Eskola J, Ahman H, Kayhty H
Vaccine
. 1999 Apr;
17(15-16):1970-7.
PMID: 10217596
Avidity of antibodies to Streptococcus pneumoniae type 6B, 14, 19F and 23F polysaccharides (PS) evoked by four different pneumococcal conjugate vaccines was compared. Infants were primed with pneumococcal PS conjugated...
8.
Anttila M, Eskola J, Ahman H, Kayhty H
J Infect Dis
. 1998 Jun;
177(6):1614-21.
PMID: 9607841
Relative avidity of IgG to Streptococcus pneumoniae type 6B and 23F polysaccharides (PSs) was measured in sera of children immunized with pneumococcal vaccines, using an EIA and the chaotropic agent...
9.
Ahman H, Kayhty H, Lehtonen H, Leroy O, FROESCHLE J, Eskola J
Pediatr Infect Dis J
. 1998 Apr;
17(3):211-6.
PMID: 9535248
Background: Pneumococcal polysaccharide vaccines are not protective against the most common pneumococcal infections in infancy. The importance of pneumococcal diseases and emerging antimicrobial resistance emphasize the need for prophylaxis. Methods:...
10.
Ahman H, Kayhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J
Pediatr Infect Dis J
. 1996 Feb;
15(2):134-9.
PMID: 8822286
Background: The emergence of resistant pneumococci makes the treatment of pneumococcal diseases difficult. The currently available polysaccharide vaccines have very limited efficacy in young children. The immunogenicity can be improved...